Lexicon Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1995-01-01
- Employees
- 285
- Market Cap
- $621.7M
- Website
- http://www.lexpharma.com
- Introduction
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
- Conditions
- Drug Interactions
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02157558
- Locations
- 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States
An Open-Label Food Effect Study of Telotristat Etiprate
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT02157584
- Locations
- 🇺🇸
Lexicon Investigational Site, Madison, Wisconsin, United States
A Thorough QT Study of Telotristat Etiprate
- Conditions
- QT Interval
- Interventions
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT02155205
- Locations
- 🇺🇸
Lexicon Investigational Site, Evansville, Indiana, United States
A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02147808
- Locations
- 🇺🇸
Lexicon Investigational Site, Madison, Wisconsin, United States
Telotristat Etiprate for Carcinoid Syndrome Therapy
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT02063659
- Locations
- 🇬🇧
Lexicon Investigational Site, Newcastle upon Tyne, United Kingdom
🇳🇱Lexicon Investigative Site, Rotterdam, Netherlands
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT02026063
- Locations
- 🇬🇧
Lexicon Investigational Site, Newcastle-Upon-Tyne, United Kingdom
🇨🇦Lexicon Investgational Site, Calgary, Alberta, Canada
An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
- Conditions
- Carcinoid Syndrome
- Interventions
- Drug: 500 mg [14C]-LX1606
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2013-10-23
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT01932528
- Locations
- 🇬🇧
Lexicon Investigational Site, Nottingham, United Kingdom
Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT01916863
- Locations
- 🇺🇸
Lexicon Investigational Site, Chula Vista, California, United States
Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: LX4211 400 mgDrug: LX4211 800 mgDrug: LX4211 Placebo
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT01916850
- Locations
- 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States
Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT01913002
- Locations
- 🇺🇸
Lexicon Investigational Site, Austin, Texas, United States